Greg is active in the biotechnology, molecular diagnostics, medical device and healthcare services sectors. He was the founding CEO of Amicus Therapeutics, Inc. (Nasdaq: FOLD) where he played a key role in identifying and licensing the technology platform, hiring the management team and developing the company's strategic plan. He also served as President of VaxInnate Corporation during its early development and is currently Executive Chairman at Resolvyx Pharmaceuticals, Inc.

Greg also serves on the IAVI Innovation Fund Venture Advisory Committee and on the board of the Connecticut Venture Group.

Prior to joining CHL Medical Partners in 2001, Greg was a Senior Associate at Whitney & Co. Earlier in his career, Greg was with the healthcare Corporate Finance Group at Morgan Stanley & Co. where he worked on financings and merger and acquisition assignments for a number of biotechnology, pharmaceutical and healthcare services clients.

Greg is a graduate of Harvard College, Harvard Medical School and Harvard Business School, where he was a Baker Scholar.

Greg can be reached at gweinhoff@chlmedical.com.


Celula, Inc.
Fidelis SeniorCare, Inc.
Resolvyx Pharmaceuticals, Inc.